TNFRSF17 and Miyoshi myopathy: Teclistamab is a bispecific antibody that targets multiple myeloma (MM) by binding to B-cell maturation antigen (BCMA) on MM cells and CD3 on T cells, triggering a T-cell-mediated anti-tumor response.